Business Description
Obsidian Therapeutics is a Cambridge, Massachusetts-based biotech company focused on developing advanced cell and gene therapies for cancer treatment. Its lead therapy, OBX-115, is currently being tested in clinical trials for patients with advanced melanoma, solid tumors, and certain forms of lung cancer. The company's core technology allows doctors to fine-tune how therapeutic proteins work inside the body using existing approved medications, which may improve both the effectiveness and safety of treatment. Founded in 2015, Obsidian works with partner organizations to broaden the application of its platform across different disease areas.
